A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 3 Study to Assess the Efficacy and Safety of TDLP-110 (Ketotransdel, Ketoprofen 10% Cream) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2012
At a glance
- Drugs Ketoprofen (Primary)
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Imprimis Pharmaceuticals
- 04 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Oct 2010 New trial record